Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 747.65M |
| Revenue (ttm) | 32.03M |
| Net Income (ttm) | -70.06M |
| Shares Out | 31.84M |
| EPS (ttm) | -2.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,722 |
| Open | 23.74 |
| Previous Close | 24.02 |
| Day's Range | 23.16 - 24.36 |
| 52-Week Range | 12.82 - 28.65 |
| Beta | 1.39 |
| Analysts | Buy |
| Price Target | 57.85 (+146.3%) |
| Earnings Date | May 5, 2022 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, I...
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is 57.85, which is an increase of 146.33% from the latest price.
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 15.83% and 48.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022. That same day, Mirum will h...
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on M...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
Moore Kuehn, PLLC Encourages Investors of Mirum Pharmaceuticals, Inc. to Contact Law Firm
New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Mirum Pharmaceutic...
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 4.91% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transpla...
FOSTER CITY, Calif.--(BUSINESS WIRE)--6-Year Natural History Comparison with Mirum's LIVMARLI Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with ALGS
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Ala...
FOSTER CITY, Calif.--(BUSINESS WIRE)--The Lancet Publishes Data from the ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
Mirum's treatment for a rare liver disorder gets FDA approval
Shares of Mirum Pharmaceuticals Inc. MIRM, -0.43% gained 2.3% in premarket trading on Thursday, the day after the company announced that the Food and Drug Administration had approved Livmarli as a treat...
FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma
The FDA has approved Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Livmarli...
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic P...
FOSTER CITY, Calif.--(BUSINESS WIRE)--FDA Approves LIVMARLI as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with ALGS